Your browser doesn't support javascript.
loading
Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant.
Zhao, Zheng; Song, Zhangjun; Wang, Xuwei; Sun, Haifeng; Yang, Xiaomin; Yuan, Yong; Yu, Pan.
Afiliação
  • Zhao Z; Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital.
  • Song Z; Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi'an.
  • Wang X; Marketing Department, Novogene Bioinformatics Institute, Beijing.
  • Sun H; Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital.
  • Yang X; Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi'an.
  • Yuan Y; Pathology Department, Shannxi Provincial Cancer Hospital, Xi'an, People's Republic of China.
  • Yu P; Marketing Department, Novogene Bioinformatics Institute, Beijing.
Onco Targets Ther ; 10: 4129-4133, 2017.
Article em En | MEDLINE | ID: mdl-28860822
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article